New studies examining one of the most severe influenza seasons in recent U.S. history are shedding light on the effectiveness of flu vaccines and raising important questions about whether standard vaccine doses provide sufficient protection for older adults.
The 2024–2025 influenza season resulted in exceptionally high hospitalization and mortality rates across the United States, with health authorities estimating hundreds of thousands of flu-related hospitalizations and tens of thousands of deaths. Children were also heavily affected, with pediatric flu-related deaths reaching record levels.
Amid the challenging season, researchers analyzed vaccination outcomes among more than one million individuals tested for influenza between October 2024 and May 2025. The findings indicated that people who received a flu vaccine were significantly less likely to contract the virus compared with those who remained unvaccinated.
The study also found that vaccinated adults aged 65 and older who later tested positive for influenza had a lower risk of dying from flu-related complications within 30 days of diagnosis, highlighting the continued importance of annual vaccination among older populations.
Health experts note that aging naturally weakens the immune system, making it more difficult for older adults to mount a strong response to standard vaccines. This reduced immune response has led to the development of high-dose influenza vaccines specifically designed for individuals aged 65 and above.
Unlike standard flu shots, high-dose vaccines contain a larger amount of antigen, the component that stimulates the body's immune response. The goal is to generate stronger protection against infection and severe illness among older adults, who face the highest risk of complications from influenza.
A separate review of multiple clinical trials involving more than 600,000 participants examined whether the higher-dose formulation provided measurable benefits. Researchers found that older adults who received the high-dose vaccine experienced lower rates of flu-related hospitalization compared with those who received standard-dose vaccines.
The analysis reported reductions in hospital admissions linked to laboratory-confirmed influenza, pneumonia and cardiorespiratory complications. Benefits were observed across different age groups, including adults over 80 years old, as well as individuals with and without underlying heart conditions.
However, researchers noted that while high-dose vaccines appeared effective in reducing hospitalizations, the studies did not find a statistically significant difference in overall mortality rates between recipients of high-dose and standard-dose formulations.
Public health specialists say the findings could influence future vaccination recommendations, particularly for older adults who remain at increased risk of severe influenza-related illness. Reducing hospitalizations not only benefits patients but can also help ease pressure on healthcare systems during severe flu seasons.
Researchers acknowledged that some of the studies included in the review received industry funding and noted that additional research across diverse populations may help further clarify the long-term benefits of high-dose influenza vaccines.
Despite ongoing discussions about optimal vaccine formulations, health authorities continue to recommend annual influenza vaccination for everyone aged six months and older. Experts say the growing body of evidence increasingly suggests that enhanced vaccine options may provide added protection for older adults, particularly during severe flu seasons.